期刊
LEUKEMIA & LYMPHOMA
卷 62, 期 12, 页码 2928-2938出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2021.1948031
关键词
SARS-CoV-2; COVID-19; acute myeloid leukemia; hematological malignancies
This multicenter observational study found a higher mortality rate in AML patients with SARS-CoV-2 infection. Factors influencing mortality included age, gender, active leukemia, severity of symptoms, etc. Certain medications and biochemical markers may have a protective effect in lowering the mortality rate.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces higher morbidity and mortality in hematological malignancies, but evidence in acute myeloid leukemia (AML) is scarce. A multicenter observational study was conducted to determine the clinical outcomes and assess the impact of therapeutic approaches in adult AML patients with SARS-CoV-2 infection in the first wave (March-May 2020). Overall, 108 patients were included: 51.9% with active leukemia and 70.4% under therapeutic schedules for AML. Signs and symptoms of SARS-CoV-2 were present in 96.3% of patients and 82.4% received specific treatment for SARS-CoV-2. The mortality rate was 43.5% and was correlated with age, gender, active leukemia, dyspnea, severe SARS-CoV-2, intensive care measures, neutrophil count, and D-dimer levels. A protective effect was found with azithromycin, lopinavir/ritonavir, and normal liver enzyme levels. During the SARS-CoV-2 first wave, our findings suggested an increased mortality in AML in a short period. SARS-CoV-2 management could be guided by risk factors in AML patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据